A Double-blind, Randomized Controlled Trial of Ciplukan (Physalis angulata Linn) Extract on Skin Fibrosis, Inflammatory, Immunology, and Fibrosis Biomarkers in Scleroderma Patients.
Dewi, Isbagio, Purwaningsih, et al. Acta medica Indonesiana, 2019.
Study design: Double-blind randomized clinical trial at Cipto Mangunkusumo Hospital and Hasan Sadikin Hospital in patients with stable scleroderma; ciplukan extract 3 x 250 mg per day for 12 weeks in addition to standard therapy.
- A total of 59 subjects completed the study: 29 in the ciplukan group and 30 in the placebo group.
- Skin fibrosis scores (MRSS) fell by 35.9 percent compared with 6.3 percent with placebo.
- P1NP levels fell by a relative 17.8 percent compared with 0.7 percent with placebo.
- There was no fall in ESR, BAFF, or sCD40L in either group.
What it means for your product: Local clinical evidence that jamu ingredients rarely have. The population was patients on medical therapy, so this is dossier and educational material, not a consumer product claim.









